Unlocking the potential of
genomic medicine

2018 News Releases

Date Title
Toggle Summary10/15/2019
PHILADELPHIA , Oct. 15, 2019 /PRNewswire/ -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX, "the Company") today announced that the Nasdaq Hearings Panel has agreed to the transfer of the Company's shares to the Nasdaq Capital Market effective at the open of business on October 15, 2019 and granted the
Toggle Summary08/07/2019
Plan to enter Phase 2 in Adult Onset Still's Disease and other serious rare and orphan diseases PHILADELPHIA , Aug. 7, 2019 /PRNewswire/ -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX, "Aevi") today announced that it has obtained the right to exercise an exclusive global license for MEDI2338, a Phase
Toggle Summary08/06/2019
PHILADELPHIA , Aug. 6, 2019 /PRNewswire/ -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX, "the Company") today announced that Michael F. Cola , President and Chief Executive Officer, will present at the 2019 Wedbush PacGrow Healthcare Conference on Tuesday, August 13, 2019 at 1:20 p.m.
Toggle Summary07/15/2019
Entering Phase 2 clinical trials for the treatment of Lymphatic Malformations which include a number of rare and orphan diseases. PHILADELPHIA , July 15, 2019 /PRNewswire/ -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX, "Aevi") today announced it has entered into an exclusive license agreement with
Toggle Summary01/02/2019
PHILADELPHIA , Jan. 2, 2019 /PRNewswire/ --  Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) ("the Company") today announced that the ASCEND trial, a genomically-guided Phase 2 double-blind, placebo-controlled clinical trial of orally-administered AEVI-001 (100 – 400 mg BID) in children aged 6 – 17 with